X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Addressing barriers that inhibit value-based contracts

By Katie Koziara  |    February 21, 2020
With 56 new medicines approved by the U.S. Food and Drug Administration (FDA) in 2019 and over 8,000 medicines in development around the globe, innovative medicines are transforming the way we treat...   Read More

New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

By Katie Koziara  |    November 4, 2019
A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....   Read More

Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

By Guest Contributor  |    September 4, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Setting the record straight on international reference pricing

By Kevin Haninger  |    July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...   Read More

Fact Check: How the Part B International Pricing Index model threatens patient access

By Nicole Longo  |    March 29, 2019
Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around about...   Read More

New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid

By Katie Koziara  |    March 20, 2019
A new analysis from Xcenda found that if Medicaid were to use one-size-fits-all value assessments like the Institute for Clinical and Economic Review’s (ICER) framework as the basis for accessing a...   Read More

PhRMA comments to administration on Medicare Part D proposed rule

By Juliet Johnson  |    January 25, 2019
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the CMS proposed rule, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and...   Read More

ICYMI: New study reinforces dangers of proposed IPI model

By Nicole Longo  |    January 15, 2019
Stakeholder after stakeholder has raised concerns that the Department of Health and Human Services’ proposed International Pricing Index (IPI) Model would put patient access to medicines in Medicare...   Read More

Groups sound the alarm on administration’s new Part B proposal

By Nicole Longo  |    November 14, 2018
Last month, the Administration announced a dangerous new proposal, the International Pricing Index Model, that would upend the delivery of Medicare Part B medicines. As PhRMA President and CEO...   Read More

4 things you need to know about the administration’s latest Part B proposal

By Nicole Longo  |    November 5, 2018
The Department of Health and Human Services (HHS) recently released an Advance Notice of Proposed Rulemaking regarding Medicare Part B that puts patient access to medicines and Part B at risk....   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates